A 28-year-old woman from Mumbai presents with a 7-day history of high-grade fever, severe headache, and altered mental status. On examination, she is febrile (40.2°C), confused, with neck stiffness and positive Kernig's sign. Her blood pressure is 92/58 mmHg, respiratory rate 28/min, and oxygen saturation 88% on room air. Laboratory investigations show hemoglobin 7.8 g/dL, WBC 12,500/μL, platelets 35,000/μL, serum creatinine 2.8 mg/dL, and serum bilirubin 6.2 mg/dL. Peripheral blood smear reveals 5% parasitemia with multiple ring forms and absent mature forms. What is the most appropriate immediate management?

Question

A 28-year-old woman from Mumbai presents with a 7-day history of high-grade fever, severe headache, and altered mental status. On examination, she is febrile (40.2°C), confused, with neck stiffness and positive Kernig's sign. Her blood pressure is 92/58 mmHg, respiratory rate 28/min, and oxygen saturation 88% on room air. Laboratory investigations show hemoglobin 7.8 g/dL, WBC 12,500/μL, platelets 35,000/μL, serum creatinine 2.8 mg/dL, and serum bilirubin 6.2 mg/dL. Peripheral blood smear reveals >5% parasitemia with multiple ring forms and absent mature forms. What is the most appropriate immediate management?

Accepted Answer

B. Intravenous artesunate 2.4 mg/kg at 0, 12, 24 hours, then daily; supportive care including blood transfusion and mechanical ventilation if needed. ## Management of Severe Malaria: Intravenous Artesunate

### Clinical Diagnosis: Severe Plasmodium falciparum Malaria

**Key Point:** This patient has **severe malaria** with multiple organ dysfunction:
- **Cerebral malaria:** Altered mental status, neck stiffness, Kernig's sign
- **Acute kidney injury:** Serum creatinine 2.8 mg/dL (>3× normal)
- **Severe anemia:** Hemoglobin 7.8 g/dL
- **Thrombocytopenia:** Platelets 35,000/μL
- **Severe jaundice:** Bilirubin 6.2 mg/dL
- **Respiratory distress:** RR 28/min, SpO₂ 88% (acute respiratory distress syndrome)
- **Hypotension:** BP 92/58 mmHg (shock)
- **High parasitemia:** >5% with absent mature forms (sequestration in microvasculature)

### Why Intravenous Artesunate?

**High-Yield:** WHO and Indian guidelines (NVBDCP 2023) mandate **intravenous artesunate** as the first-line treatment for severe malaria worldwide, including India. Artesunate is superior to quinine and artemether in reducing mortality.

| Parameter | IV Artesunate | IM Artemether | IV Quinine |
|-----------|---------------|---------------|------------|
| **Mortality reduction** | 35% vs quinine | Comparable to IV artesunate | Baseline |
| **Onset of action** | Rapid (peak 1–2 hrs) | Slower (IM absorption) | Slower |
| **Organ dysfunction reversal** | Superior | Good | Inferior |
| **Hypoglycemia risk** | Lower | Lower | **Higher** |
| **Cardiac arrhythmias** | Rare | Rare | **Common** |
| **Dosing** | 2.4 mg/kg IV at 0, 12, 24 hrs, then daily | 3.2 mg/kg IM loading, then 1.6 mg/kg daily | 20 mg/kg loading over 4 hrs, then 10 mg/kg q8h |

**Clinical Pearl:** Quinine causes **hypoglycemia** (stimulates pancreatic insulin release) and **cardiac toxicity** (QT prolongation, arrhythmias), making it unsuitable in this hypotensive, critically ill patient. Artemether (IM) is acceptable but slower than IV artesunate.

### Dosing Regimen for IV Artesunate
1. **Loading dose:** 2.4 mg/kg IV at 0, 12, and 24 hours
2. **Maintenance:** 2.4 mg/kg IV once daily from day 4 onwards
3. **Switch to oral ACT** (artemether-lumefantrine or dihydroartemisinin-piperaquine) once patient can tolerate oral intake (usually day 3–4)

### Supportive Management (Equally Critical)

**Mnemonic:** **CRASH-BANG** (Cerebral malaria, Renal failure, Acidosis, Severe anemia, Hypoglycemia, Bleeding, Acute respiratory distress, Hypotension, Neurological sequelae, Glucose monitoring)

1. **Blood transfusion:** Hemoglobin 7.8 g/dL → transfuse PRBCs to target Hb >7 g/dL (or >10 g/dL if cerebral malaria)
2. **Mechanical ventilation:** SpO₂ 88% + RR 28 → intubate if ARDS develops
3. **Renal replacement therapy:** Creatinine 2.8 mg/dL → monitor urine output; initiate dialysis if oliguria/hyperkalemia
4. **Glucose monitoring:** Hypoglycemia is common; maintain blood glucose >100 mg/dL
5. **Platelet transfusion:** Only if active bleeding (platelets 35,000/μL alone is not an indication)
6. **Fluid management:** Careful hydration; avoid fluid overload (risk of pulmonary edema in AKI)
7. **Antimicrobial coverage:** Empiric antibiotics for bacterial meningitis until CSF culture rules it out

**Warning:** Do NOT use oral artemisinin monotherapy or oral quinine in severe malaria — parenteral therapy is mandatory.

### Why NOT the Other Options?

**Option 1 (Correct):** IV artesunate with aggressive supportive care is the gold standard.

**Option 2 (IM artemether):** While artemether is effective, IM administration is slower than IV artesunate. In a critically ill patient with cerebral malaria and shock, IV artesunate achieves faster parasite clearance and organ recovery.

**Option 3 (IV quinine):** Quinine is associated with:
- Hypoglycemia (dangerous in this patient)
- Cardiac arrhythmias (QT prolongation)
- Higher mortality compared to artesunate
- No longer recommended by WHO for severe malaria

**Option 4 (Oral artemether-lumefantrine):** Oral therapy is contraindicated in severe malaria with altered mental status, hypotension, and organ dysfunction. Parenteral therapy is mandatory.

[cite:WHO Guidelines for Malaria 2023; NVBDCP Malaria Treatment Guidelines India 2023; Harrison 21e Ch 217]

Answer

A. Oral artemether-lumefantrine 6 tablets twice daily for 3 days; supportive care with antipyretics and analgesics

Answer

C. Intramuscular artemether 3.2 mg/kg loading dose, then 1.6 mg/kg daily; oral follow-up with artemisinin-based combination therapy

Answer

D. Intravenous quinine 20 mg/kg loading dose over 4 hours, then 10 mg/kg every 8 hours; switch to oral quinine after fever subsides

Explanation

Practice similar questions